One To Watch

Biovac

A Cape Town-based specialist vaccine manufacturer building Africa's first end-to-end multi-vaccine production facility to strengthen the continent's health security and vaccine self-reliance.

Company Overview

A Cape Town-based specialist vaccine manufacturer building Africa's first end-to-end multi-vaccine production facility to strengthen the continent's health security and vaccine self-reliance. Biovac occupies a rare position in African life sciences as a domestically rooted biopharma company focused exclusively on vaccine development and manufacturing. The company's mission centers on reducing Africa's dependence on imported vaccines by building sovereign, scalable production capacity on the continent. Its work spans technology transfer, fill-and-finish manufacturing, and now full end-to-end production of multiple vaccine types.

Headquarters and Global Presence

Biovac is headquartered in Cape Town, South Africa, and operates its manufacturing plant within the Western Cape. Its operational partnerships and financing relationships extend across Europe, North America, and multilateral development institutions globally.

Founding and History

Biovac, formally known as The Biovac Institute, was established as a public-private partnership to address South Africa's vaccine manufacturing gap. The company achieved an early milestone by partnering with Pfizer and BioNTech to manufacture the COVID-19 mRNA vaccine for distribution across Africa, marking a watershed moment for continental vaccine production. Subsequent years have seen Biovac attract a growing consortium of development finance institutions, culminating in a landmark financing package announced in April 2026.

Therapy Areas and Focus

Biovac's work is concentrated entirely on infectious disease prevention through vaccines, targeting diseases of high burden across sub-Saharan Africa and the broader continent. Key vaccine types in scope include inactivated polio vaccines, COVID-19 vaccines, and a range of additional antigens targeted through its expanding multi-vaccine facility. The strategic rationale is clear: Africa imports the vast majority of its vaccines, leaving the continent exposed to supply disruptions, pricing pressures, and inequitable access during global health emergencies. Biovac's model aims to reverse that dependency by anchoring production capability locally.

Technology Platforms and Modalities

Biovac's manufacturing platform encompasses fill-and-finish operations as well as the development of full end-to-end vaccine production — a capability that Africa has not previously possessed at scale. The end-to-end model covers antigen production, formulation, filling, and packaging entirely within a single facility, eliminating critical import dependencies at each stage. Technology transfer agreements with global vaccine majors, including Sanofi for inactivated polio vaccine and Pfizer/BioNTech for mRNA COVID-19 vaccine, have been central to building out this platform capability. This positions Biovac not merely as a contract manufacturer but as a growing center of vaccine science and process development.

Key Pipeline and Programs

**Inactivated Polio Vaccine (IPV) — Partnership with Sanofi:** Announced in June 2024, Biovac and Sanofi entered a partnership to produce inactivated polio vaccines in Africa. This technology transfer targets one of the continent's most persistent immunization challenges and represents a significant step toward locally manufactured routine immunization antigens.

**COVID-19 Vaccine Manufacturing — Pfizer/BioNTech:** Biovac was selected by Pfizer and BioNTech to manufacture their COVID-19 mRNA vaccine for African distribution, a deal that accelerated the company's technical capabilities and global profile. This program established Biovac's credentials for complex biologics manufacturing.

**Multi-Vaccine End-to-End Facility:** The flagship project underpinning Biovac's long-term strategy is its new multi-vaccine manufacturing facility, described as Africa's first end-to-end plant of its kind. Supported by a nine-partner development consortium and anchored by the EIB's planned €175 million investment, the facility is designed to produce multiple vaccine types and create durable continental supply capacity.

Recent Developments

In April 2026, the EIB Group, the European Commission, and the International Finance Corporation jointly announced a financing package backing Biovac's end-to-end multi-vaccine facility — the most significant capital commitment in the company's history. This followed a June 2024 announcement that the EIB was planning a €175 million investment to anchor the facility's development. Also in June 2024, Biovac formalized its partnership with Sanofi for inactivated polio vaccine production in Africa. A nine-partner development consortium has been assembled to expand Biovac's manufacturing plant capacity across multiple vaccine programs.

Key Personnel

Biovac operates under executive leadership drawn from South Africa's public health and biopharma sectors. The company functions as a public-private partnership, meaning its governance structure includes both private management and public sector stakeholders. Specific named executives are not detailed in available sources, though its leadership team has successfully negotiated deals with Pfizer, BioNTech, Sanofi, the EIB, IFC, and the European Commission — reflecting strong institutional credibility and negotiating capability.

Strategic Partnerships

Biovac's partnership portfolio is among the most substantial assembled by any African vaccine manufacturer. Key relationships include Sanofi (inactivated polio vaccine technology transfer), Pfizer and BioNTech (COVID-19 vaccine manufacturing), and a nine-member development consortium supporting facility expansion. On the financing side, the EIB, European Commission, and IFC have committed to the end-to-end facility, with the EIB's contribution alone planned at €175 million.

FAQ Section

Africa imports the vast majority of its vaccines, a vulnerability exposed acutely during the COVID-19 pandemic when wealthy nations secured supply ahead of lower-income markets. Biovac is addressing this directly by building Africa's first end-to-end multi-vaccine manufacturing facility in South Africa, capable of producing antigens, formulating, filling, and packaging entirely on the continent. Backed by a €175 million EIB investment and co-support from the IFC and European Commission, the company represents the most advanced effort to create durable vaccine self-reliance in sub-Saharan Africa.

Fill-and-finish manufacturing — the stage at which bulk antigen supplied from elsewhere is filled into vials and packaged — has existed in Africa but leaves the continent dependent on imported bulk vaccine material. End-to-end manufacturing covers the entire production chain, from antigen synthesis through formulation, filling, and final packaging, eliminating that upstream import dependency. Biovac's new facility will be the first on the continent to achieve this for multiple vaccine types simultaneously, a qualitative leap in regional capability.

Rather than licensing finished products, Biovac has secured technology transfer agreements with Sanofi for inactivated polio vaccine and with Pfizer and BioNTech for mRNA COVID-19 vaccine manufacturing. These deals transfer the actual production knowledge and processes to Biovac's South African facility, building institutional capability that persists beyond any single product deal. Combined with development finance backing from multilateral institutions, this positions Biovac as a long-term platform for African vaccine science rather than a transactional contract manufacturer.

Biovac and Sanofi formalized a partnership in June 2024 to produce inactivated polio vaccines in Africa, with Sanofi providing technology transfer to enable local production. Inactivated polio vaccine is a cornerstone of routine childhood immunization schedules across the continent and has historically been imported entirely from manufacturers in high-income countries. Localizing this production addresses both cost and supply security for one of Africa's most essential immunization antigens.

Biovac operates exclusively within infectious disease prevention, with its portfolio spanning polio, COVID-19, and a broader range of vaccine antigens targeted through its multi-vaccine facility. The company's scope is defined less by specific pathogens and more by the manufacturing platform's ability to accommodate multiple modalities — inactivated virus vaccines, mRNA vaccines, and others as technology transfer deals expand. This flexibility is central to the facility's value proposition as a continental resource rather than a single-product plant.

The financing package from the EIB Group, European Commission, and IFC was announced in April 2026, confirming that capital mobilization for the facility is substantially complete. The nine-partner development consortium has been assembled, and the EIB's planned €175 million commitment represents the anchor investment. Specific construction timelines and projected operational dates have not been publicly disclosed, but the April 2026 financing announcement marks the transition from deal-making to active development.

Key watchpoints for Biovac include:

**Facility construction milestones:** Progress toward operational status for the end-to-end multi-vaccine plant will be the primary near-term indicator of execution capability.
**Technology transfer completion:** The pace at which Sanofi's IPV and Pfizer/BioNTech's COVID-19 vaccine processes are fully transferred and validated in South Africa.
**Financing disbursement:** Whether the EIB's €175 million commitment and IFC co-financing convert from pledged to disbursed capital on schedule.
**Regulatory pathway:** South African Health Products Regulatory Authority (SAHPRA) approval of domestically manufactured products will be a critical milestone before commercial supply can begin.
**Geopolitical and procurement risk:** Uptake of locally manufactured vaccines by African Union member states and GAVI-funded programs will determine commercial viability.

Want to Update your Company's Profile?